Blue Jet Healthcare Ltd. ||Q4 FY25 Results

📊 Blue Jet Healthcare Ltd. ||
Q4 FY25 Results

➡️ Revenue from Operations
₹340.05 crore (QoQ: +6.8%, YoY: +84.9%)

➡️ Profit Before Tax (PBT)
₹147.22 crore (QoQ: +11.0%, YoY: +171.9%)

➡️ Net Profit (PAT)
₹110.10 crore (QoQ: +11.2%, YoY: +177.6%)

➡️ Earnings Per Share (EPS)
₹6.35 (QoQ: +11.2%, YoY: +177.3%)

🔹 Overall Verdict: Blockbuster
➤ Robust growth across topline and bottom line with sustained margin strength and operating efficiency.

🔍 What the Numbers Say
🔹 Revenue Performance
➤ Strong YoY revenue surge (+85%) driven by growth across sweeteners, contrast media intermediates, and pharma APIs. QoQ sequential uptick (+6.8%) despite Q4 seasonality reflects resilient volume and/or price growth.

🔹 Profitability Insights
➤ PBT more than doubled YoY. Impact of depreciation method change (WDV to SLM) enhanced PBT by ₹35.87 crore in Q4. Margins benefited from scale, operating leverage, and stable input costs.

🔹 Cost & Efficiency
➤ Controlled employee and finance costs. Operating margins expanded, and depreciation declined due to accounting method change, which boosted profitability.

🔹 Strategic / Operational Highlights
➤ Final dividend of ₹1.2/share declared.
➤ Fund raise of up to ₹1,500 crore approved via QIP/preferential issue.
➤ Land acquisition at Dahej for capacity expansion.
➤ Appointment of new senior leadership to drive strategy.

Comments

Popular posts from this blog

Finance company Sundaram Finance announced Q4FY25 & FY25 results*

📊 Indian, US, and European stock markets for the week ending August 3, 2025 along with details on top gainer and loser companies, Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) activities, bonds, gold, and other relevant market updates.

STOCK MARKET ANALYSIS UPDATES. WEEK ENDING MAY 2, 2025 👇